期刊文献+

^(131)I治疗分化型甲状腺癌转移灶中甲状腺球蛋白测定和^(131)I-全身显像的意义 被引量:5

The value of thyroglobulin measured and ^(131)I-whole body scan on the differentiated thyroid carcinoma with ^(131)I
原文传递
导出
摘要 目的探讨分化型甲状腺癌转移灶治疗中131I-全身显像(131I-WBS)和甲状腺球蛋白(Tg)测定的意义。方法39例分化型甲状腺癌患者术后4~6周用131I行首次清除残余甲状腺治疗,3~6个月后重复治疗,治疗中131I-WBS和Tg测定同期完成。结果在首次清除残余甲状腺治疗时显像发现淋巴、肺及骨转移灶有11例,其余转移灶于重复治疗时发现。131I治疗分化型甲状腺癌转移灶,以淋巴转移效果最好,肺转移次之,骨转移最差。有8例患者(20.5%)Tg测定与131I-WBS不符。结论131I治疗分化型甲状腺癌转移灶效果好,患者存活率高;131I-WBS和Tg测定在分化型甲状腺癌随访中应联合应用,互相补充。 Objective To investigate the valve of ^131I - whole body scan (^131I-WBS) and thyroglobulin (Tg) on the differentiated thyroid carcinoma with ^131I, Methods The first ablation thyroid emnant at after thyroidectomy 4-6 weeks for all patients reseived ^131I 1,11 GBq, 1,85 GBq, 2.96 GBq, 3.7 GBq, respratery, The metestases patients retreatment was after 3-6 months, ^131I single doses rangging from 4.81-7.40 GBq. All patients were performed ^131I-WBS and measured serum Tg. Results 28 patients (71,8%) had successful ablation remnant tissue at first therapy, 11 patients have been found metastases in first thrapy, The effection of tretment were best for patients with lymph metastases, and the patients of lung metastases were better, there was no significant effect for patients with bone metastases, Tg measurements were 20.5% cases inconsistent with ^131I-WBS . Conclusions ^131I therapy is an effective methoud to treat the patients with differentiated thyroid carcinomatous metastases and enhance the patients' livability. The mensuration of ^131I- WBS and Tg should be combined operate to recruit reciprocally.
出处 《国际放射医学核医学杂志》 2006年第3期161-162,167,共3页 International Journal of Radiation Medicine and Nuclear Medicine
关键词 甲状腺肿瘤 碘放射性同位素 甲状腺球蛋白 Thyroid neoplasms Iodineradioisotopes Thyroglobulin
  • 相关文献

参考文献4

  • 1Pacini F, Agate L, Elisei R. Outcome of differentiated thyroid cancer with detectable serum Tg and negative ^131I whole body scan: comparison of patients treated with high ^131I activities versus untreated. J Clin Endocrinol Metab, 2001, 86(9): 4092-4097.
  • 2马超,匡安仁.分化型甲状腺癌随访中^(131)I全身显像阴性但Tg阳性的原因及对策[J].中华核医学杂志,2004,24(1):55-57. 被引量:11
  • 3Jana S, Abdel-Dayem HM, Young I. Nuclear medicine and thyroid cancer. Eur J Nucl Med, 1999, 26 (12) : 1528-1532.
  • 4谭天秩.放射性核素治疗.谭天秩,主编.临床核医学.北京:人民卫生出版社,2003.1255.

二级参考文献3

  • 1T. Petrich,A. B?rner,D. Otto,M. Hofmann,W. Knapp. Influence of rhTSH on [18F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma[J] 2002,European Journal of Nuclear Medicine and Molecular Imaging(5):641~647
  • 2Michaela Diehl,J?rn H. Risse,Katja Brandt-Mainz,Markus Dietlein,Karl H. Bohuslavizki,Peter Matheja,Heike Lange,Jan Bredow,Carsten K?rber,Frank Grünwald. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study[J] 2001,European Journal of Nuclear Medicine(11):1671~1676
  • 3Fran?oise Aubène Leger,Mireille Izembart,Fran?oise Dagousset,Lionel Barritault,Georges Baillet,Alain Chevalier,Jér?me Clerc. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma[J] 1998,European Journal of Nuclear Medicine(3):242~246

共引文献10

同被引文献23

  • 1罗全勇,朱瑞森.分化型甲状腺癌患者血清Tg和TgAb检测与结果分析应注意的问题[J].国外医学(放射医学核医学分册),2004,28(5):197-199. 被引量:13
  • 2袁耿彪,匡安仁.钠碘转运体与分化型甲状腺癌[J].中国介入影像与治疗学,2005,2(1):6-9. 被引量:3
  • 3陆汉魁,余永利,罗全勇,陈立波,朱瑞森.^(131)I治疗分化型甲状腺癌合并远处转移的疗效及影响因素[J].上海第二医科大学学报,2005,25(12):1263-1266. 被引量:29
  • 4吴涛,张瑜庆,纪宗正,陈熹.青少年分化型甲状腺癌的诊断和治疗[J].临床外科杂志,2006,14(3):142-144. 被引量:4
  • 5Nikiforova MN,Kimura ET,Gandhi M,et al.BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.J Clin Endocrinol Metab,2003,88 (11):5399-5404.
  • 6Quiros RM,Ding HG,Gattuso P,et al.Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.Cancer,2005,103 (11):2261-2268.
  • 7Gruning T,Tiepolt C,Zophel K,et al.Retinoic acid for redifferentiation of thyroid cancer--does it hold its promise? Eur J Endocrinol,2003,148(4):395-402.
  • 8Schmutzler C,Hoang-Vu C,Rüger B,et al.Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses.Eur J Endocrinol,2004,150(4):547-556.
  • 9Simon D,Koehrle J,Reiners C,et al.Redifferentiation therapy with retinoids:therapeutic option for advanced follicular and papillary thyroid carcinoma.World J Surg,1998,22(6):569-574.
  • 10Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ab- lation of thyroid remnants after preparation with recombinant hu- man thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. Clin Endocrinol Metab, 2006,91(3) :926-932.

引证文献5

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部